Exian Mou
Overview
Explore the profile of Exian Mou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu S, Yu M, Mou E, Wang M, Liu S, Xia L, et al.
Sci Rep
. 2025 Jan;
15(1):713.
PMID: 39753653
The efficacy of neoadjuvant therapy varies significantly with hormone receptor (HR) status for patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC). Despite extensive research on...
2.
Mou E, Ji J, Liu S, Shu L, Zou L, Li Z
Sci Rep
. 2024 Nov;
14(1):26364.
PMID: 39487187
Explore whether the axillary outcomes differ among HER2 positive subgroups receiving standard dual-targeted therapy, aiming to identify subgroups exhibiting enhanced sensitivity to NAT among HER2-positive/node-positive breast cancer patients. HER2 positive...
3.
Xu J, Li X, Zhang P, Luo J, Mou E, Liu S
Oncol Lett
. 2024 May;
28(1):311.
PMID: 38784604
[This retracts the article DOI: 10.3892/ol.2022.13268.].
4.
Yu M, Xia L, Cao B, Wang M, Liu S, Liu S, et al.
Gland Surg
. 2023 Mar;
12(2):165-182.
PMID: 36915807
Background: The prognosis of multifocal multicentric breast cancer (MIBC) was related to many factors, and there are different recommendations for surgical approaches. We compare the effects of breast-conserving surgery (BCS)...
5.
Xu J, Li X, Zhang P, Luo J, Mou E, Liu S
Oncol Lett
. 2022 Mar;
23(5):147.
PMID: 35350590
Breast cancer (BC) is a commonly identified life-threatening type of cancer and a major cause of death among women worldwide. Several microRNAs (miRs), including miR-143-5p, have been reported to be...
6.
Ran R, Tu G, Li H, Wang H, Mou E, Liu C
J Oncol
. 2021 Dec;
2021:9967599.
PMID: 34950210
Purpose: With the increasing incidence of thyroid cancer (TC), associations between genetic polymorphisms and TC risk have attracted a lot of attention. Considering that the results of associations of genetic...
7.
Li B, Xia L, Yang J, Wen M, Yu M, Mou E, et al.
Gland Surg
. 2021 Aug;
10(7):2220-2231.
PMID: 34422593
Background: Patient delay commonly appears in breast cancer (BC), but the findings for influential factors may be contaminated by recall bias. The real factors in patient delay (divided into appraisal...
8.
Liu S, Mou E, Zeng S, Wang L, Dong H, Ji J, et al.
Cancer Manag Res
. 2020 May;
12:3145-3153.
PMID: 32440212
Purpose: The aim of the present study was to investigate the effect of trastuzumab on the pathological complete response (pCR) rate and event-free survival (EFS) in neoadjuvant-treated HER2-positive breast cancer...
9.
Mou E, Wang H
Biosci Rep
. 2019 Aug;
39(9).
PMID: 31399501
Triple-negative breast cancer (TNBC) is a subtype of aggressive breast cancer with high recurrence and poor survival. Emerging evidence has indicated that long non-coding RNAs (lncRNAs) play pivotal roles in...